|
Real-time Estimate
Cboe BZX
16:56:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.200 USD | -2.44% |
|
+26.79% | -84.20% |
Company Valuation: Decoy Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 22.39 | 3.485 | 2.56 | 2.652 | 4.142 | 0.8059 | - |
| Change | - | -84.43% | -26.55% | 3.58% | 56.21% | -80.54% | - |
| Enterprise Value (EV) | 22.39 | 3.485 | 2.56 | 2.652 | 4.142 | 0.8059 | 0.8059 |
| Change | - | -84.43% | -26.55% | 3.58% | 56.21% | -80.54% | 0% |
| P/E | -1.6x | - | -0.17x | -0.32x | -0.06x | -0.14x | -0.15x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | - | 0x | 0x | 0x | 0.02x |
| Capitalization / Revenue | 12,167,670x | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | -0x | -0.08x | -0.04x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -11,160 | - | -5,530 | -1,042 | -129.1 | -8.96 | -8.28 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales | 1.84 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | -12.61 | -10.2 | -19.1 |
| Net income 1 | -12.77 | -31.61 | -12.54 | -5.576 | -12.52 | -10.1 | -19.1 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 17,841.586 | 2,203.200 | 936.000 | 331.200 | 7.786 | 1.230 | 1.230 |
| Nbr of stocks (in thousands) | 1.26 | 1.58 | 2.74 | 8.01 | 532 | 655.2 | - |
| Announcement Date | 3/10/22 A | 3/27/23 A | 3/22/24 A | 3/21/25 A | 3/31/26 A | - | - |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.14x | - | - | - | 806K | |
| 16.97x | 6.42x | 12.3x | 1.76% | 64.38B | |
| 30.03x | 8.21x | 26.91x | 0.04% | 56.16B | |
| 37.32x | 6.62x | 19.78x | 0.87% | 54.16B | |
| 35.94x | 3.4x | 14.66x | -.--% | 45.33B | |
| 49.01x | 5.65x | 30.93x | -.--% | 42.25B | |
| -19.75x | 191.25x | -21.04x | -.--% | 40.78B | |
| 46.05x | 8.16x | 27.33x | -.--% | 33.8B | |
| 31.61x | 8.04x | 20.91x | 0.41% | 32.25B | |
| 27.18x | 5.72x | 14.84x | -.--% | 23.57B | |
| Average | 25.42x | 27.05x | 16.29x | 0.34% | 39.27B | |
| Weighted average by Cap. | 27.79x | 25.71x | 16.39x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- DCOY Stock
- Valuation Decoy Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
